Jennifer Taylor-Cousar is a Respiratory physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Jackson St
National Jewish Health
Denver, CO 802062761
Telephone
303-388-4461Provider last certified this registry record 12 Nov 2020.
Clinical trials
4 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20252 payments
- Avanos MedicalProgram year20251 payment
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20249 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
49.1%Other respiratory system products36.3%Trikafta91%Symdeko9%Part D<11 patientsbeta2-Adrenergic Agonist9.5%Ventolin Hfa51%Albuterol Sulfate Hfa49%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
21.5%Antidiarrheal microorganisms9.2%Creon56%Zenpep44%Part D<11 patientsProton pump inhibitor7.2%Omeprazole100%Part D<11 patients+ 1 more class in this area
Nervous system
9.5%Azaspirodecanedione derivatives3.3%Buspirone Hcl100%Part D<11 patientsTricyclic Antidepressant3.1%Amitriptyline Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2011–2015 per NIH RePORTER. The latest:
- Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF
National Jewish Health
FY2015$120,732K23HL103801 - Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF
National Jewish Health
FY2014$151,048K23HL103801 - Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of CF
National Jewish Health
FY2013$151,340K23HL103801
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”